ArticleScience signaling2018
Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).
Open access · greenAbstract read
In one paragraph
Article in Science signaling, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
3.5field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 73 citations in OpenAlex.
- Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2023Trial
- Efficacy and Determinants of Response to HER Kinase Inhibition inCancer discovery · 2020Trial
- Article
- Review
- Review
- Efficacy and Safety Ranking of HER2-Targeted TKIs in Advanced Breast Cancer: A Bayesian Network Meta-Analysis.Clinical Medicine Insights. Oncology · 2026Article
- Detection of heterogeneous resistance mechanisms to tyrosine kinase inhibitors from cell-free DNA.Cell genomics · 2025Article
- Disentangled contrastive learning with dynamic intent adaptation for unveiling gene-drug associations.Briefings in bioinformatics · 2025Article
- Beyond Hormone Receptors: liquid biopsy tools to unveil new clinical meanings and empower therapeutic decision-making in Luminal-like metastatic breast cancer.Breast (Edinburgh, Scotland) · 2025Review
- Genetic Alterations in HER2-Positive and Equivocal Breast Cancer by Immunohistochemistry.Breast cancer (Dove Medical Press) · 2025Article
- HER2-Positive Breast Cancer Treatment and Resistance.Advances in experimental medicine and biology · 2025Review
- HER2 mutation as an emerging target in advanced breast cancer.Cancer science · 2024Review
- TH-4000, a hypoxia-activated pan-HER inhibitor, shows excellent preclinical efficacy for the treatment of HER2Archives of toxicology · 2024Article
- Dynamic changes in tumor profiling reveal intra- and inter-tumoral heterogeneity focused on an uncharacterized HER2 mutation: a case report of a young breast cancer patient.Frontiers in oncology · 2024Article
- Clinical characteristics and treatment outcomes of HER2 mutation and HER2 fusion in 22 patients with advanced breast cancer.Thoracic cancer · 2023Article
- Neratinib for HER2-positive breast cancer with an overlooked option.Molecular medicine (Cambridge, Mass.) · 2023Review
- Irreversible HER2 inhibitors overcome resistance to the RSL3 ferroptosis inducer in non-HER2 amplified luminal breast cancer.Cell death & disease · 2023Article
- Targeting HER2-positive breast cancer: advances and future directions.Nature reviews. Drug discovery · 2023Review
- The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer.Frontiers in pharmacology · 2023Review
- Somatic Mutations ofJournal of breast cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 6 institutions in 4 countries.
Emiliano CoccoHuman Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
F Javier CarmonaHuman Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
Pedram RazaviHuman Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
Helen H WonHuman Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
Yanyan CaiHuman Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.ORCID 0000-0002-2779-6163
Valentina RossiUnit of Investigative Clinical Oncology (INCO), Candiolo Cancer Institute, FPO-IRCCS, Str. Provinciale 142, 10060 Candiolo, Italy.ORCID 0000-0003-2471-7500
Carmen ChanHuman Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.ORCID 0000-0001-9086-6622
James CownieHuman Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
Joanne SoongHuman Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.ORCID 0000-0002-8220-1601
Eneda ToskaHuman Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.ORCID 0000-0002-8974-9792
Sophie G ShifmanHuman Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.ORCID 0000-0002-5794-1691
Ivana SarottoUnit of Surgical Pathology, Fondazione del Piemonte per l'Oncologia, Candiolo Cancer Institute, FPO-IRCCS, Str. Provinciale 142, 10060 Candiolo, Italy.ORCID 0000-0002-6958-5698
Peter SavasDivision of Research and Cancer Medicine, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC 3000, Australia.ORCID 0000-0001-5999-428X
Michael J WickSTART, 4383 Medical Dr, San Antonio, TX 78229, USA.ORCID 0000-0001-5683-8687
Kyriakos P PapadopoulosSTART, 4383 Medical Dr, San Antonio, TX 78229, USA.ORCID 0000-0002-0667-2620
Alyssa MoriartySTART, 4383 Medical Dr, San Antonio, TX 78229, USA.
Richard E CutlerPuma Biotechnology Inc., 10880 Wilshire Blvd, Los Angeles, CA 90024, USA.
Francesca Avogadri-ConnorsPuma Biotechnology Inc., 10880 Wilshire Blvd, Los Angeles, CA 90024, USA.ORCID 0000-0003-0671-0620
Alshad S LalaniPuma Biotechnology Inc., 10880 Wilshire Blvd, Los Angeles, CA 90024, USA.
Richard P BrycePuma Biotechnology Inc., 10880 Wilshire Blvd, Los Angeles, CA 90024, USA.
Sarat ChandarlapatyHuman Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.ORCID 0000-0003-4532-8053
David M HymanDepartment of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.ORCID 0000-0001-8150-9762
David B SolitHuman Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.ORCID 0000-0002-6614-802X
Valentina BoniSTART Madrid, Centro Integral Oncológico Clara Campal, Hospital Universitario Madrid Sanchinarro, Calle de Oña 10, 28050 Madrid, Spain.ORCID 0000-0002-8675-0018
Sherene LoiDivision of Research and Cancer Medicine, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC 3000, Australia.ORCID 0000-0001-6137-9171
José BaselgaHuman Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.ORCID 0000-0003-1361-4063
Michael F BergerHuman Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.ORCID 0000-0003-3882-5000
Filippo MontemurroUnit of Investigative Clinical Oncology (INCO), Candiolo Cancer Institute, FPO-IRCCS, Str. Provinciale 142, 10060 Candiolo, Italy. filippo.montemurro@ircc.it scaltrim@mskcc.org.ORCID 0000-0003-4231-2291
Maurizio ScaltritiHuman Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. filippo.montemurro@ircc.it scaltrim@mskcc.org.ORCID 0000-0002-5522-1447
Memorial Sloan Kettering Cancer Center · USPuma Biotechnology (United States) · USCandiolo Cancer Institute · ITSouth Texas Accelerated Research Therapeutics · USPeter MacCallum Cancer Centre · AUHospital Universitario HM Sanchinarro · ES
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MUnraveling resistance to PI3K-alpha inhibitors in breast cancerR01CA190642 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SCALTRITI, MAURIZIO · 2015 to 2019
$2.2MThe possible role of the novel Akt 3 R247C mutation in opposing to anti-HER2 therR03CA187094 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SCALTRITI, MAURIZIO · 2014 to 2015
$176kNCI NIH HHS P30 CA008748NCI NIH HHS R01 CA190642NCI NIH HHS R03 CA187094
Abstract
Mutations in
Indexed as
AnimalsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCell Line, TumorDrug Resistance, NeoplasmErb-b2 Receptor Tyrosine KinasesFemaleHumansLapatinibLung NeoplasmsMiceMice, NudeMutationProportional Hazards ModelsProtein Kinase InhibitorsAntineoplastic AgentsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesLapatinibneratinibProtein Kinase InhibitorsQuinolinesTrastuzumab
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.